» Articles » PMID: 25452994

Management of Prostate Cancer in Port Harcourt, Nigeria: Changing Patterns

Overview
Specialty General Medicine
Date 2014 Dec 3
PMID 25452994
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This is a follow up to a study done at the University of Port Harcourt Teaching Hospital (UPTH) 11 years ago on the management of prostate cancer.

Aims: To assess the current pattern in the management of prostate cancer in Port Harcourt, Nigeria and the impact of changes in diagnosis and treatment.

Methods: All the case notes of prostate cancer presenting in the University of Port Harcourt Teaching Hospital between January 2003 and December 2012 were reviewed. Data on demography, clinical presentations, co-morbidities, investigations, treatment, complications and outcome of treatment were extracted and analyzed using SPSS 20.0 0 RESULTS: A total of 294 histologically confirmed patients with cancer of the prostate were treated within the study period. Out of these, 216 (73.5%) case notes were analysed. The mean age was 69.9 years (51 -90 years). All the patients had lower urinary tract symptoms, 30 (14.0%) had haematuria while 19(8.8%) presented with paraplegia. The prostate specific antigen (PSA) ranged from 0.5 - 760ng/ml. Two hundred and five (95%) received androgen deprivation therapy. Of these, 123 (60%) had bilateral subcapsular orchidectomy and anti androgen, 3 (1.4%) had abiraterone. Five (2.3%) had radical prostatectomy, 22 (10.2%) had chemotherapy while 16(7.4%) had radiotherapy. Seventy-two (33.5%) died within 2 years of diagnosis while 49(30.2%) survived more than 5 years.

Conclusion: There is rising prevalence of carcinoma of the prostate in this centre. Many patients presented late. There has been expansion in diagnostic and therapeutic capabilities with attendant improvement in patients' survival. Co-morbidities adversely affected the outcome of treatment.

Citing Articles

Sociodemographic and clinicopathologic characteristics of patients treated with high dose rate prostate brachytherapy in Nigeria.

Abdus-Salam A, Jimoh M, Folasire A, Ntekim A, Ojo O, Ehiedu C Ecancermedicalscience. 2024; 18:1740.

PMID: 39421165 PMC: 11484653. DOI: 10.3332/ecancer.2024.1740.


Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review.

Iheanacho C, Enechukwu O Cancer Causes Control. 2024; 36(1):1-12.

PMID: 39306811 DOI: 10.1007/s10552-024-01917-w.


Pattern, Clinical Characteristics, and Impact of Family History on Prostate-Specific Antigen in Prostate Cancer: A Multicenter Study.

Iheanacho C, Odili V, Enakirerhi G, Isiwele E, Essiet A Am J Mens Health. 2024; 18(4):15579883241264949.

PMID: 39054776 PMC: 11282506. DOI: 10.1177/15579883241264949.


Testicular Disease: A Clinico-Pathological Report from a Nigerian Tertiary Health Center.

Emmanuel I, Akpa P, Amaike C, Winnie J, Otene B, Dallang B Niger Med J. 2024; 64(3):307-313.

PMID: 38974059 PMC: 11223012.


Cigarette Smoking, Alcohol Consumption, and the Risk of Prostate Cancer-A Retrospective Analysis of Prostate Cancer Patients in Southern Nigeria.

Raphael J, Ekeke O Niger Med J. 2024; 62(6):346-352.

PMID: 38736515 PMC: 11087687. DOI: 10.60787/NMJ-62-6-66.


References
1.
Raynaud J . Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem Mol Biol. 2009; 114(1-2):96-105. DOI: 10.1016/j.jsbmb.2009.01.014. View

2.
Potosky A, Miller B, Albertsen P, Kramer B . The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273(7):548-52. View

3.
Hindson B, Turner S, Do V . Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Australas Radiol. 2007; 51(6):584-8. DOI: 10.1111/j.1440-1673.2007.01897.x. View

4.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

5.
Moul J . Targeted screening for prostate cancer in African-American men. Prostate Cancer Prostatic Dis. 2002; 3(4):248-255. DOI: 10.1038/sj.pcan.4500472. View